Literature DB >> 7597376

Influence of nifedipine on plasma membrane fluidity and oxidative burst of polymorphonuclear leucocytes.

W Grassi1, R Serretti, P Core, S Muti, C Cervini.   

Abstract

It has been demonstrated that the calcium antagonist nifedipine inhibits the reactive oxygen species (ROS) production by polymorphonuclear leucocytes (PMNLs) activated with phorbol myristate acetate (PMA), but the mechanism underlying this effect is still unknown. In the present study we investigated the influence of nifedipine on the PMNL plasma membrane using 1-(4-trimethylaminophenyl)-6-phenyl-1,3,5,hexatriene (TMA-DPH) fluorescence polarization (P) and on PMA- and N-formyl-methionyl-leucyl-phenylalanine (FMLP)-induced ROS production, measured by luminol-dependent chemiluminescence (CL). The plasma membrane fluidity of untreated PMNLs, expressed as P, was 0.371 +/- 0.008. After preincubation of 15 min, nifedipine induced a significant change in P values only at a concentration of 10(-4) M (P = 0.00018). After preincubation of 60 min significant changes in P values were also observed at concentrations of 10(-6) M (P = 0.023) and 10(-7) M (P = 0.023). PMA-induced ROS production by PMNLs was markedly inhibited by nifedipine. Nifedipine also determined a striking change in the FMLP-induced CL response, characterized by both an overall inhibition of PMNL activity and a modification of the kinetics of the oxidative burst (rapid increase in ROS production followed by a pronounced drop in the PMNL response). Such a pattern was found at concentrations of 10(-4) M (preincubation time: 15 min), 10(-6) M and 10(-7) M (preincubation time: 60 min). These findings indicate that nifedipine directly interacts with the PMNLs by inducing a marked decrease in plasma membrane fluidity and an inhibition of the oxidative burst.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7597376     DOI: 10.1007/BF00262086

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  28 in total

1.  The effect of diltiazem on calcinosis in a patient with the CREST syndrome.

Authors:  M J Farah; G M Palmieri; J I Sebes; M A Cremer; J D Massie; R S Pinals
Journal:  Arthritis Rheum       Date:  1990-08

2.  Calcium channel antagonist induced inhibition of superoxide production in human neutrophils. Mechanisms independent of antagonizing calcium influx.

Authors:  K Irita; I Fujita; K Takeshige; S Minakami; J Yoshitake
Journal:  Biochem Pharmacol       Date:  1986-10-15       Impact factor: 5.858

3.  Preparation and assay of superoxide dismutases.

Authors:  J D Crapo; J M McCord; I Fridovich
Journal:  Methods Enzymol       Date:  1978       Impact factor: 1.600

Review 4.  The cell biology of multiple drug resistance.

Authors:  W T Beck
Journal:  Biochem Pharmacol       Date:  1987-09-15       Impact factor: 5.858

5.  A rapid one-step procedure for purification of mononuclear and polymorphonuclear leukocytes from human blood using a modification of the Hypaque-Ficoll technique.

Authors:  A Ferrante; Y H Thong
Journal:  J Immunol Methods       Date:  1978       Impact factor: 2.303

6.  Nifedipine in digital ulceration in scleroderma.

Authors:  I A Jaffe
Journal:  Arthritis Rheum       Date:  1982-10

7.  Plasma membrane fluidity measurements on whole living cells by fluorescence anisotropy of trimethylammoniumdiphenylhexatriene.

Authors:  J G Kuhry; G Duportail; C Bronner; G Laustriat
Journal:  Biochim Biophys Acta       Date:  1985-04-22

8.  Polymorphonuclear neutrophil function in systemic sclerosis.

Authors:  L Czirják; K Dankó; S Sipka; M Zeher; G Szegedi
Journal:  Ann Rheum Dis       Date:  1987-04       Impact factor: 19.103

9.  Vertical displacement of membrane proteins mediated by changes in microviscosity.

Authors:  H Borochov; M Shinitzky
Journal:  Proc Natl Acad Sci U S A       Date:  1976-12       Impact factor: 11.205

10.  White blood cell activation in Raynaud's phenomenon of systemic sclerosis and vibration induced white finger syndrome.

Authors:  C S Lau; A O'Dowd; J J Belch
Journal:  Ann Rheum Dis       Date:  1992-02       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.